Welcome!

News Feed Item

Sernova Provides Corporate Update and Results of 2014 Annual General Meeting

LONDON, ONTARIO -- (Marketwired) -- 06/03/14 -- Sernova Corp. (TSX VENTURE:SVA), a clinical stage company developing medical technologies for the long-term treatment of chronic debilitating metabolic diseases including diabetes and haemophilia today provides a corporate update and results of its 2014 Annual General Meeting (AGM).

Dr. Philip Toleikis, CEO of Sernova, commented, "This is an exciting time for Sernova. We are continuing our Cell Pouch(TM) clinical trial with Dr. James Shapiro of the University of Alberta for the treatment of Type I diabetes, and have reached agreement with Medicyte Gmbh for the initiation of proof of concept studies of our Cell Pouch(TM) with Factor VIII producing cells to treat haemophilia. We have also increased our board membership and brought on several seasoned business development members to assist the Sernova team as we further develop the Company."

Dr. Toleikis further stated, "Along with our current programs, we are seeking to develop additional clinical applications for the Cell Pouch(TM), and our new business development team is in discussions with other potential corporate and academic partners to further expand the depth of our technologies. These advances should continue to build shareholder value and benefit patients with chronic diseases."

Selected 2013 and 2014 Corporate Developments

Following are highlights of significant developments at Sernova during the past year:


--  Released positive interim results from our human clinical trial of the
    Cell Pouch(TM) with insulin producing islets for the treatment of Type I
    diabetes, demonstrating biocompatibility and safety for up to 6 months,
    as well as proof of 30 day islet survival within the Cell Pouch(TM)
    following islet transplant. The clinical trial is ongoing. 
--  Established an agreement with Medicyte GmbH and initiated preclinical
    studies to jointly evaluate the use of Medicyte's upcyte® cells in
    Sernova's Cell Pouch(TM) to treat patients with haemophilia A. 
--  Received the first patent allowance for Methods and Devices for Cellular
    Transplantation from the Australian Patent Office. 
--  Continued evaluation of our Sertolin(TM) local immune protection
    technology within the Cell Pouch(TM) for treatment of chronic diseases
    following receipt of a contribution agreement for up to $254,300 from
    the National Research Council of Canada for continued research and
    development. 
--  Closed non-brokered private placement of $2 million, comprising 10
    million units at a price of $0.20. Each unit consisted of 1 common share
    and 1 common share purchase warrant exercisable at $0.35 for the first
    24 months and $0.40 for the subsequent 12 months. 
--  Appointed biopharma entrepreneur and investor Frank Holler to the Board
    of Directors. 
--  Established a world class business development team of Kevin Egan and
    Nick Borrelly to establish corporate partners for Sernova's programs and
    to expand Sernova's proprietary technologies through academic and
    corporate partnerships. 
--  Appointed Mr. David Garland CPA CA, CPA CMA, MAcc, BA(Hon) as interim
    CFO to replace Ms. Cathy Steiner, who has moved on to pursue other
    business interests. Mr. Garland has extensive public company experience
    and has been CFO of Highcourt Partners, LTD, Mash Media Solutions, Inc.,
    and Wi-LAN V-chip Corp and has worked as VP Finance and/or Controller at
    Pathways to Education, Certicom Corp, and Delano Technology Corporation.

2014 AGM Appointments


--  Dr. George Adams (Chair), Frank Holler, Jeffrey Bacha, James Parsons,
    Bruce Weber and Dr. Philip Toleikis, were elected as the directors of
    the Company to hold office until the next annual general meeting of
    shareholders. 
--  Davidson & Company, Chartered Accountants, was appointed auditor of the
    Company until the close of the next annual general meeting of
    shareholders, at a remuneration to be fixed by the Directors. 

About Sernova

Sernova Corp is a clinical stage regenerative medicine company developing medical technologies for the treatment of chronic debilitating metabolic diseases such as diabetes, blood disorders including haemophilia and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. Sernova is developing the Cell Pouch(TM), an implantable medical device for therapeutic cells (donor, xenogeneic or stem cells) which then release proteins and/or hormones as required. The therapeutic cells are protected from immune attack by Sernova's proprietary technologies.

Forward Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Every successful software product evolves from an idea to an enterprise system. Notably, the same way is passed by the product owner's company. In his session at 20th Cloud Expo, Oleg Lola, CEO of MobiDev, will provide a generalized overview of the evolution of a software product, the product owner, the needs that arise at various stages of this process, and the value brought by a software development partner to the product owner as a response to these needs.
"Plutora provides release and testing environment capabilities to the enterprise," explained Dalibor Siroky, Director and Co-founder of Plutora, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
SYS-CON Events announced today that Enzu will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Enzu’s mission is to be the leading provider of enterprise cloud solutions worldwide. Enzu enables online businesses to use its IT infrastructure to their competitive ad...
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operations and Information Security organizations together. Capital Ones DevOpsSec practice is based upon three "pillars" – Shift-Left, Automate Everything, Dashboard Everything. Within about three years, from 100% waterfall, C...
SYS-CON Events announced today that MobiDev, a client-oriented software development company, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place June 6-8, 2017, at the Javits Center in New York City, NY, and the 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software company that develops and delivers turn-key mobile apps, websites, web services, and complex softw...
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
Internet of @ThingsExpo, taking place June 6-8, 2017 at the Javits Center in New York City, New York, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @ThingsExpo New York Call for Papers is now open.
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
SYS-CON Events announced today that Catchpoint Systems, Inc., a provider of innovative web and infrastructure monitoring solutions, has been named “Silver Sponsor” of SYS-CON's DevOps Summit at 18th Cloud Expo New York, which will take place June 7-9, 2016, at the Javits Center in New York City, NY. Catchpoint is a leading Digital Performance Analytics company that provides unparalleled insight into customer-critical services to help consistently deliver an amazing customer experience. Designed ...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
While many government agencies have embraced the idea of employing cloud computing as a tool for increasing the efficiency and flexibility of IT, many still struggle with large scale adoption. The challenge is mainly attributed to the federated structure of these agencies as well as the immaturity of brokerage and governance tools and models. Initiatives like FedRAMP are a great first step toward solving many of these challenges but there are a lot of unknowns that are yet to be tackled. In hi...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.